Sat, Apr 19, 2014, 7:23 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • jrlanah jrlanah Sep 13, 2011 8:08 AM Flag

    news out

    Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

    Last update: 9/13/2011 7:00:06 AM

    -Companies to combine proprietary technologies to generate novel ADC product candidates-


    BOTHELL, Wash. & OXFORD, England, Sep 13, 2011 (BUSINESS WIRE) -- Seattle Genetics, Inc. (SGEN) and Oxford BioTherapeutics (OBT) today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP(R)) database. The antibodies generated by OBT will then be screened for activity using Seattle Genetics' ADC technology. The resulting ADCs may be selected by each company for further development and commercialization.

    "This collaboration is directly aligned with our goal of identifying novel ADC targets to expand our early-stage product pipeline," said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. "Through the agreement, we contribute our know-how and proprietary ADC technology and gain access to novel cancer targets obtained from OBT's expertise in target discovery. We believe that this type of multi-product collaboration maximizes the chances for success and capitalizes on each company's strengths."

    "We are delighted to be collaborating with Seattle Genetics in this alliance which we believe will add multiple ADC candidates to OBT's rapidly developing pre-clinical product pipeline. ADCs are beginning to transform the outlook for many cancer patients and OBT believes that with its antibody pipeline, it can make an important contribution to the development of this exciting new class of therapeutics. We are looking forward to working with Seattle Genetics to provide improved therapies for patients suffering from cancer," said Christian Rohlff, Chief Executive Officer of OBT.

    Under the terms of the multi-year, multi-product agreement, OBT and Seattle Genetics will each have an equal number of alternating options to select programs from among the preclinical ADCs identified for exclusive, worldwide development and commercialization. Each company will receive undisclosed progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by the other party.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • riceenseenmstoknowethefuture riceenseenmstoknowethefuture Sep 13, 2011 8:46 PM Flag

      This was from the " Riceen Letter".

      "This collaboration is directly aligned with our goal of identifying novel ADC targets to expand our early-stage product pipeline," said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. "Through the agreement, we contribute our know-how and proprietary ADC technology and gain access to novel cancer targets obtained from OBT's expertise in target discovery. We believe that this type of multi-product collaboration maximizes the chances for success and capitalizes on each company's strengths."

      "We are delighted to be collaborating with Seattle Genetics in this alliance which we believe will add multiple ADC candidates to OBT's rapidly developing pre-clinical product pipeline. ADCs are beginning to transform the outlook for many cancer patients and OBT believes that with its antibody pipeline, it can make an important contribution to the development of this exciting new class of therapeutics. We are looking forward to working with Seattle Genetics to provide improved therapies for patients suffering from cancer," said Christian Rohlff, Chief Executive Officer of OBT.

      Under the terms of the multi-year, multi-product agreement, OBT and Seattle Genetics will each have an equal number of alternating options to select programs from among the preclinical ADCs identified for exclusive, worldwide development and commercialization. Each company will receive undisclosed progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by the other party.

      • 1 Reply to riceenseenmstoknowethefuture
      • This was from the " Riceen Letter".

        "This collaboration is directly aligned with our goal of identifying novel ADC targets to expand our early-stage product pipeline," said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. "Through the agreement, we contribute our know-how and proprietary ADC technology and gain access to novel cancer targets obtained from OBT's expertise in target discovery. We believe that this type of multi-product collaboration maximizes the chances for success and capitalizes on each company's strengths."

        "We are delighted to be collaborating with Seattle Genetics in this alliance which we believe will add multiple ADC candidates to OBT's rapidly developing pre-clinical product pipeline. ADCs are beginning to transform the outlook for many cancer patients and OBT believes that with its antibody pipeline, it can make an important contribution to the development of this exciting new class of therapeutics. We are looking forward to working with Seattle Genetics to provide improved therapies for patients suffering from cancer," said Christian Rohlff, Chief Executive Officer of OBT.

        Under the terms of the multi-year, multi-product agreement, OBT and Seattle Genetics will each have an equal number of alternating options to select programs from among the preclinical ADCs identified for exclusive, worldwide development and commercialization. Each company will receive undisclosed progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by the other party.


        Rating :
        (1 Rating)

    • This is a big deal. This allows SGEN to have a constant flow of drug candidates that most of big pharma can not replicate. Most of the drugs developed in the Oxford Genome Anatomy Project would be novel and attacking cancer in areas where survival has be bleek.

      Great move for the longs.

      • 1 Reply to barthoganjr
      • AGREED that the collaborative arrangement with Oxford is an excellent move HOWEVER, for those like myself who desire the prospect of Seattle remaining a takeover target to big pharma, I must be concerned about the contractual details of the just announced agreement. The devil is always in the details!

        Will the Oxford collaboration impact Seattle's desirability to big pharma as a takeover target or not?

 
SGEN
38.84+0.27(+0.70%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST